Researchers developed a second-generation NTB bicyclic peptide library, identifying NT-B2R, a peptide that effectively targets MYC, a key factor in most human cancers, demonstrating its potential in inhibiting MYC transcription activities and cancer cell proliferation.
FDA delays action on Lilly’s donanemab, intent on advisory committee meeting – Pharmaceutical Technology
Share this article Lilly is looking to join Eisai’s Lequembi on the market for the treatment of Alzheimer’s. Credits: SewCreamStudio/Shutterstock.com As Eli Lilly’s donanemab inches
March 8, 2024